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ABSTRACT 
Alhayyani, Sultan. M.S. Microbiology and Immunology Graduate Program, Wright 
State University, 2014. Expression of the Alpha, Beta, and Gamma Subunits of 
the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells. 
 
 
Interleukin 2 (IL-2) is a member of the cytokine family and contributes to 
the proliferation, survival, and death of lymphocytes [1]. The interleukin-2 
receptor (IL-2) is a tripartite receptor commonly expressed on the surfaces of 
many lymphoid cells and is composed of three non-covalently associated 
subunits, alpha (α) (CD25), beta (β) (CD122), and gamma (γ) (CD132) [2]. Our 
laboratory has previously described IL-2 receptor β (IL-2Rβ) expression by 
vasculature smooth muscle cells (VSMC) in mice and humans [3]. The current 
work expands our previous observations by assessing the expression of the 
alpha and gamma subunits of the IL-2R by VSMCs. Analysis of IL-2R expression 
in human VSMCs revealed no detectable expression of the gamma subunit and 
low expression of the alpha subunit. Treatment of VSMCs with IL-2 induced 
VSMC proliferation with a concomitant increase in the expression of the gamma 
subunit while having no detectable effect on expression of the alpha or beta 
subunits. Treatment of VSMCs with LPS decreased expression of the beta 
subunits and had little effect on alpha or gamma expression. Understanding the 
mechanisms that regulate expression of the IL-2R by VSMCs and how binding of 
this receptor by IL-2 mediates VSMC proliferation will provide a better 
understanding of vascular biology and possible mechanisms underlying vascular 
diseases such as atherosclerosis. 
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 1 
Introduction 
Smooth muscle is an involuntary non-striated muscle found within blood 
vessel walls and many other many tissues. Bundles of myosin and actin 
filaments within individual smooth muscle cells allow for contraction and 
relaxation resulting in changing the shape and stiffness of hollow organs. 
Contraction of vascular smooth muscle cells (VSMC) is responsible for the 
redistribution of blood to areas where it is needed by altering local blood pressure 
[4].  
Interleukin 2 (IL-2) is a 15 kD glycoprotein and member of the cytokine 
family. IL-2 regulates immune cell function by promoting the proliferation, 
survival, and cell death of lymphocytes expressing the IL-2 receptor (IL-2R) [1].  
The IL-2R is a tripartite receptor composed of three non-covalently associated 
subunits, alpha (α)(CD25), beta (β) (CD122), and gamma (γ) (CD132). The β and 
α subunits of the receptor bind to IL-2 while the β and γ subunits are responsible 
for signal transduction [2]. 
Our laboratory has previously shown that SMCs within blood vessels of IL-
2 deficient mice exhibit a loss of smooth muscle cells compared to wild-type 
controls [3]. Additional work from our lab described expression of the IL-2Rβ by 
murine and human vascular smooth muscle cells [3]. The current work expands 
our previous observations by assessing the expression of the α and γ subunits by 
VSMCs. Analysis of IL-2R expression human VSMCs revealed no detectable 
expression of the γ subunit and little expression of the α subunit. Exposure of 
VSMCs to IL-2 increased VSMC proliferation with a concomitant increase in the 
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expression of the γ subunit while having little effect on expression of the α and 
the β subunits. In addition, exposure of VSMCs to bacterial lipopolysaccharide 
(LPS), which has been reported to activate SMCs through interaction with the 
Toll Like Receptor 4 (TLR4) [5], decreased the expression of β subunit while 
having little effect on the expression of α and γ. These results suggest that IL-2 
and factors that activate SMCs may have a direct effect on expression of the IL-
2R subunits by SMCs. 
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Hypothesis: Human Vascular Smooth Muscle Cells (VSMC) express all 
three subunits () of the IL-2R. 
 
 
 
 
 
 
Aims of the current study: 
 Determine which subunits of the IL-2 receptor are expressed by 
smooth muscle cells. 
 Determine how activation of smooth muscle cells impacts IL-2R 
expression.  
 Assess how IL-2 affects smooth muscle cell function. 
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Literature Background 
 
Smooth Muscle cells: 
Smooth muscle is an involuntary non-striated muscle found within many 
tissues including blood vessel walls, lymphatic vessels, the gastrointestinal and 
respiratory tracts, and iris of the eye. Bundles of myosin and actin filaments 
within individual smooth muscle cells allow for contraction and relaxation 
resulting in changing the shape and stiffness of hollow organs [4]. 
Vascular Smooth Muscle Cells (VSMCs) are a major component of blood 
vessel walls and are responsible for altering local blood pressure thereby 
providing increased blood flow to areas where it is needed.  In addition, VSMCs 
are important in the remodeling vessel tissue by proliferation, migration, and the 
synthesis of large amounts of extracellular matrix (ECM), following pregnancy or 
vascular injury [4]. VSMCs can perform both contractile and synthetic functions, 
which are characterized by changes in morphology, proliferation, migration rates, 
and the expression of different marker proteins. Alpha -smooth muscle actin (α-
SMA), smooth muscle-myosin heavy chain (SM-MHC), and cellular retinol 
binding protein (CRBP) are some of the SMC marker proteins involved in SMC 
contraction as structural components of the contractile apparatus or as a 
contraction regulator. VSMCs in the vessel wall are diverse. This diversity is 
reflected by the differential expression of contractile marker proteins, gap of 
junction proteins, and adhesion molecules. This heterogeneous expression in 
VSMCs is attributable to variations in gene expression and consequently SMC 
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function. The diversity of VSMCs within a given length of vessel has been 
proposed to make the vessel more responsive to various physiological or 
pathological situations. In addition to their contractile and structural functions 
within the vessel wall, VSMCs synthesize, secrete, and respond to small soluble 
signaling molecules [6]. VSMCs synthesize IL-1, IL-6, IL-8, IL-11, TNF- α, 
monocyte chemotactic peptides (MCPs), and macrophage migration inhibitory 
factors (MMIFs)-1 α and -1 β [7, 8, 9, 10,11]. These cytokines and growth factors 
stimulate SMC migration as an early event in vessel remodeling [12,13]. 
 
Vascular Smooth Muscle Cells Proliferation: 
 Under normal conditions VSMCs do not proliferate [14]. However, injuries 
such as angioplasty, vascular stent implantation, or organ transplantation induce 
VSMC proliferation [14,15,16]. Growth factors including platelet-derived growth 
factor (PDGF), basic fibroblast growth factor, and insulin – like growth factor -1 
promote VSMC proliferation [17,18]. The actions of these growth factors involve 
nuclear factors including c-fos and c-myc that become active when the growth 
factors bind to their respective cell surface tyrosine kinase receptors. These 
nuclear factors work as transcriptional factors, leading to an increase in the 
expression of various cell cycle regulatory proteins such as the cyclins and 
cyclin-dependent kinases (CDK) [18,19]. To keep the proliferative response in 
check, other factors inhibit VSMC proliferation.  Such factors include CDK 
inhibitors, which are divided into 2 different families based on their structure: the 
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INK4 family (p14, p15, p16, p18, and p19) and the KIP/CIP family (p21, p27, and 
p57) [20].  
 
Vascular Smooth Muscle Cell Migration: 
In the normal resting condition, VSMCs are non-migratory due, in part, to 
being surrounded by a highly dense and adhesive matrix and the relative 
absence of stimulatory factors [21]. Blood flow, sheer stress, cytokines, and 
peptide growth factors are some of the factors that can affect VSMC migration 
[21]. The initiation of migration begins with the activation of cell surface receptors 
such as platelet-derived growth factor (PDGF) receptors which, in turn, activate 
signal transduction pathways, trigger remodeling of cytoskeleton, decrease the 
adhesive molecules in the matrix and activate motor proteins [22]. During 
migration there is a decrease in the expression of cell-cell adhesive molecules 
and focal contacts in the trailing edge of the cell and an increase adhesion of the 
cell membrane to the matrix at the leading edge. Regulation of the actin 
cytoskeleton occurs by several signaling pathways involving molecules such as 
trimeric G proteins, small G proteins, lipid kinases, Ca2+-dependent kinases, and 
Rho kinases [23]. 
 There is also a link between migration and proliferation of VSMCs [24]. 
During VSMC proliferation, migration occurs only when the cell cycle is in the G1 
phase but not in the later phases of the cell cycle. When the proliferation of 
VSMC is inhibited by P21 and p27 proteins, inhibitors of VSMC proliferation, 
VSMC migration is also inhibited. Overexpression of these inhibitor proteins 
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leads to a reduction of human vein VSMC migration as well as proliferation [25, 
26]. 
 
Interleukin-2:  
Interleukin 2 (IL-2) is a 15 kD glycoprotein, a member of the cytokine 
family, and is produced predominately by activated CD4+ and CD8+ T cells [1]. IL-
2 regulates immune cell function by promoting proliferation, survival, and cell 
death of lymphocytes expressing the IL-2R [27]. IL-2 also acts as a down-
regulator of T cells leading to apoptosis. This feedback mechanism targets re-
activated T cells in order to restrict the expansion of antigen-specific immune 
responses [28, 29]. Other cells such as activated dendritic cells (DCs) and 
natural killer (NK) cells produce IL-2, but the biological relevance of this 
production is unclear [30, 31, 32]. IL-2 is produced following binding of the T cell 
receptor (TCR) by costimulatory molecules such as CD28 on naïve T cells.  
Transcriptional induction of the IL-2 gene is stringent. The promoter/enhancer 
region for the IL-2 gene is approximately 500 base pairs upstream of the 
transcription initiation site [33]. After TCR/costimulatory molecules bind, the TCR 
signaling induces an increase in AP-1 and NF-kB levels, which in turn cause the 
dephosphorylation of NFAT, leading to its translocation from the cytoplasm to 
nucleus [34, 35]. These transcription factors bind to specific sites within the first 
300 base pairs of the minimal promoter, leading to IL-2 gene transcription. T-box 
transcription factor (T-bet) has been recently found to repress IL-2 production 
through its interaction with Rel-A within the proximal IL-2 promoter [36]. IL-2 
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inhibits its own production through a classical auto-regulatory feedback loop, this 
loop depends on activation of signal transducer and activator of transcription-5 
(STAT-5), and the IL-2-dependent induction of the transcriptional repressor B-
lymphocytes maturation protein-1 (Blimp-1) [37]. Thus, when naïve T cells 
become activated, IL-2 is produced and binds to the IL-2 receptor (IL-2R), which, 
in turn, leads to activation of STAT-5 and induction of Blimp-1, thence IL-2 gene 
repression.  
 
Interleukin-2 Receptor: 
The IL-2R is a tripartite receptor composed of three non-covalently 
associated subunits: alpha (α; CD25), beta (β; CD122), and the gamma (γ; 
CD132). The γ subunit is common to the receptor complexes for at least six 
different interleukin receptors: IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The β and 
the γ chains are related to the class I cytokine receptor superfamily, and exhibit 
primarily folded β-sheet structures [2]. These three subunits are required for high 
affinity IL-2 binding. IL-2 initially binds only the α subunit, which then promotes 
association with the β and γ subunits. This IL-2/IL-2R quaternary complex 
induces signaling pathways through the cytoplasmic β and γ tails [38, 39]. The 
proteins Jak-3 via γ and Jak-1 via β phosphorylate key tyrosine residues, which 
leads to binding between the adaptor Shc and either Stat-3 or Stat-5. Shc 
activates two pathways: the mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K). These two pathways are important for cell 
survival and growth. After Stat is further phosphorylated, it dimerizes and 
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translocates into the nucleus to regulate genes important in growth and function 
of T cells [39]. IL-2/IL-2R binding on the cell surface is short-lived. After 10 to 20 
minutes, the IL-2/IL-2R complex is internalized into the cytoplasm. IL-2, CD122, 
and CD132 are degraded by lysosomes, whereas CD25 recycles to the cell 
surface [40, 41, 42] [43]. CD132 is a shared subunit not only for IL-2R, but also 
for IL-4, IL-7 IL-9, IL-15 and IL-21, and is expressed on all hematopoietic cells [2, 
44]. Lymphoid progenitors, NK cells, NKT cells, memory phenotypic CD8 T cells, 
and Foxp3+ Treg cells express CD122 subunit [45]. Most lymphoid cells, except 
subsets of developing pre-T and pre-B cells, do not express CD25. Activated 
effector cells, and natural CD4+ Foxp3+ Treg cells express CD25 [46].  
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Materials & Methods 
 
Human Vascular Smooth Muscle Cell Culture: 
Human aortae, obtained from organ donors, were washed with PBS and the 
adventitia was removed by gently scraping the outer surface with a scalpel blade.  
A 2 cm2 piece was placed in a Petri dish and cut into1 mm2 pieces. The pieces 
were placed lumen side down onto the surface of a TC-75 culture flask.  The 
flask was placed upright in an incubator at 37°C to allow the tissue to adhere to 
the surface of the flask.  After 4-6 hours, 10 ml of smooth muscle cell medium 
was carefully poured into the flask so as not to dislodge the tissue.  The aortic 
pieces were cultured for 1-2 weeks before removal, and remaining cells were 
passaged 4 times before use in assays. 
 
In-cell Western: 
VSMCs were cultured in black 96-well plates at an initial density of 5,000 cells 
per ml. After incubation under conditions indicated in the figure legends, cells 
were fixed in ice-cold methanol with 2% acetic acid v/v. After washing 3 times 
with Tris-buffered saline/Tween-20 (TTBS), the cells were blocked for 2 hours 
with Odyssey blocking buffer (Licor) containing 2% mouse serum. The anti-
CD25, anti-CD122, and anti-CD132 antibodies were added at 1g/well in TTBS 
and incubated with the fixed, blocked cells in triplicate overnight at room 
temperature. Isotype control antibodies were used at the same concentration as 
the primary antibodies. The next day the cultures were washed 3X with TTBS, 
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and probed for 1.5 h with streptavidin-680 (SA-680, Invitrogen) used at 1g/well 
in TTBS. After a final wash, the plate was allowed to air dry in the dark and read 
at 680 nm using a Synergy plate reader.  (For additional details see appendix A) 
 
 IL-2 Binding Studies: 
VSMC were cultured in 96-well plates at an initial density of 5,000 cells per well.  
Cells were probed with one of two different IL-2 preparations previously 
conjugated to a small molecular weight infra-red dye. Briefly, human IL-2 from a 
bacterial source (unglycosylated) or mammalian cell line (glycosylated) was 
labeled with an infrared dye (680LT, LI-COR Biosciences, Lincoln, NE) per the 
manufacturer’s instructions. The activated infra-red dye was added to the IL-2 at 
a molar ratio of 1:1. Following a 2 hour incubation at 20°C, unconjugated dye 
was removed from the preparation using a Zebra Spin de-salting column.  
Cells were probed with one of the two fluor-conjugated monomeric IL-2 
preparations at the concentrations indicated in the figure legend for 20 mins at 
4°C. To determine if antibodies against the subunit of the IL-2R would block 
binding of the fluor-IL2, some cells were pre-incubated with 40ug/ml of anti-
CD122 for 30 minutes. Cells were then fixed with ice-cold methanol with 5% 
acetic acid for 15 minutes at 4°C. The fixed cultures were washed 2 times with 
PBS and read at 680 nm using a Synergy plate reader. (For additional details 
see appendix B). 
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SMC Proliferation Assay: 
 VSMCs were cultured in clear 96-well plates at an initial density of 5,000 
cells per ml. Some cells were treated with IL-2 as indicated in the figure legend, 
and incubated for 2, 4, or 6 days.  Twenty µl of CellTiter 96 Aqueous One 
solution reagent (Promega) was added to each well of the 96-well plate 
containing the samples in 100µl of culture medium, incubated at 37°C for 1-4 
hours, then read at 490nm using a Synergy plate reader.  The CellTiter 96 
Aqueous One Solution reagent contains 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium, which is reduced by 
cells into a colored formazan product that is soluble in tissue culture medium. 
This conversion occurs by NADPH or NADH produced by dehydrogenase 
enzymes only in cells that are metabolically active. (For additional details see 
appendix C) 
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Results 
Human Vascular Smooth Muscle Cell can express the Alpha, Beta, and 
Gamma Subunits of the IL-2 Receptor. 
To determine if human vascular smooth muscle cells (HVSMC) express 
the Alpha, Beta, or Gamma subunits of IL-2R, we examined their expression 
using an In-Cell Western analysis, in which cell surface expression of receptors 
is assayed in fixed, cultured cells using fluorescently-labeled antibodies. As 
shown in Figure 1, HVSMCs express Beta subunit, and to a lesser degree the 
Alpha subunits.  Little to no expression of the Gamma subunit was detected.  
 
Dye-labeled glycosylated IL-2 binds vascular smooth muscle cells. 
In light of the above results, we next asked whether IL-2 binds the IL-2R 
expressed by HVSMCs. Cultured cells were incubated with glycosylated human 
IL-2 labeled with a fluorescent dye (680LT, LI-COR Biosciences, Lincoln, NE). 
The presence of carbohydrates mimics the in vivo situation wherein HVSMC’s 
would be exposed to a glycosylated IL-2. To confirm that retention of the fluor-IL-
2 was mediated by the IL-2R, some cells were pre-incubated with an anti-CD-122 
antibody. As seen in figure 2, fluor-monomer IL-2 bound to HVSMCs. Pre-
incubation with anti-CD-122 decreased the binding of fluor-IL-2 three fold. 
 
Dye labeled, non-glycosylated IL-2 binds vascular smooth muscle cells. 
To assess the involvement of carbohydrates on IL-2 in mediating binding 
to the IL-2R expressed by HVSMCs, binding of glycosylated fluor-IL-2 (above) 
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was compared to binding of a non- glycosylated form of recombinant IL-2.  Using 
the same procedure as detailed above, HVSMC’s were found to bind non-
glycosylated fluor-IL-2, and this binding was also inhibited by an anti-CD122 
antibody. An approximately 2 fold decrease in the binding of non-glycosylated 
fluor-IL-2 was detected in wells pre-incubated with Anti-CD122 antibody 
compared to wells probed with dye labeled non-glycosylated IL-2 alone (Figure 
3).  
 
IL-2Rβ expression decreases in vascular smooth muscle cells after 
exposure to lipopolysaccharide (LPS). 
Having confirmed that HVSMCs express the Beta and Alpha subunits of 
the IL-2R, we asked whether treatment of HVSMCs with LPS influenced IL-2R 
subunit expression. To do so, VSMC were cultured with LPS for 48 hours, and 
IL-2R expression was assessed. No appreciable change in the expression of the 
Alpha or Gamma subunits was observed in response to exposure to LPS (data 
not shown). However, Beta expression was observed to decrease (Figure 4).   
 
Exposure of Vascular Smooth Muscle Cells to IL-2 increases expression of 
the IL-2R gamma subunit (γ).   
Based on the above results, we asked how IL-2 affects IL-2R subunit expression. 
Cultured VSMCs were cultured with IL-2 for 24 hours and IL-2R subunit 
expression was assessed. Interestingly, Gamma subunit expression increased in 
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cells exposed to IL-2 compared to media only (Figure 5). No appreciable change 
occurred in Alpha and Beta expression (data not shown).  
 
Exposure of Vascular Smooth Muscle Cells to IL-2 increases SMC 
Proliferation.  
 To determine if IL-2 affects VSMC proliferation, HVSMC’s were treated with 
monomeric IL-2 and the proliferative response was assessed. Treatment of 
HVSMCs with IL-2 resulted in an approximately 25 fold-increase in the number of 
viable cells compared to wells receiving no IL-2.  
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Discussion 
Interleukin 2 is a 15-kD cytokine produced mainly by T cells.  It plays a 
critical role in regulating T cell proliferation, survival and death [1]. IL-2 binds with 
high affinity to a tripartite receptor composed of alpha (CD25) (α), beta (CD122) 
(β), and gamma (CD132) (γ) subunits that are expressed mainly on the surfaces 
of lymphoid progenitors, NK cells, NKT cells, memory T cells, and T-reg cells 
[45]. However, more recent studies from our lab and others have described 
expression of the IL-2R on non-lymphoid cells including vascular smooth muscle 
cells [47, 3]. 
Our laboratory recently described expression of the β subunit of the IL-2R 
by murine and human VSMC’s [3]. Our current work reveals that VSMCs express 
both the β and α subunits, and can be induced to increase expression of the of γ 
subunit. To examine if the glycosylation state of IL-2 affects binding to the IL-2R 
expressed on VSMC’s, we compared the binding of a glycosylated form of IL-2 
with a non-glycosylated form. No appreciable difference was detected between 
the glycosylated and non-glycosylated forms, suggesting that the IL-2R 
expressed on VSMC’s does not bind IL-2 in a carbohydrate-dependent manner. 
Since IL-2’s main function is regulating T cell proliferation, we asked if treatment 
of VSMC’s with IL-2 induces a proliferative response. Interestingly, IL-2 increases 
VSMC proliferation, suggesting that in vivo exposure of VSMC’s to IL-2 may 
affect the development of new blood vessels and/or the regeneration of 
vasculature following injury.  
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IL-2 is used as an immunotherapy due to its ability to increase T-cell 
proliferation and differentiation. Although this treatment can cause regression of 
tumor metastases, it is associated with multiple side effects including vascular 
leak syndrome, left ventricular dysfunction, increased cardiac output, and 
decreased systemic vascular resistance [48]. The most significant dose-limiting 
side effect is vascular leak syndrome, which entails increased vascular 
permeability causing a leakage of fluid from the circulatory system into the 
interstitial space resulting in ascites, hydrothorax, pulmonary edema, and 
hypotension.  
Previous studies have shown that IL-2 increases the expression of 
adhesion molecules such as ICAM-1 in endothelial cells and beta-2 integrin in 
neutrophils. Increased expression of these adhesion molecules has been 
proposed to be part of the mechanism underlying vascular leak syndrome [49, 
50]. Whether IL-2 binding to its receptor in SMCs increases expression of these 
adhesion molecules is under investigation. However, given the responsivity of 
VSMC’s to IL-2 described in the current work, it seems likely that some aspect of 
vascular leak syndrome could be caused by a direct effect of high dose IL-2 on 
VSMC’s. 
Abnormal VSMC proliferation is thought to play a critical role in 
atherosclerosis and restenosis. In response to injury of the blood vessel 
endothelial cell layer, cholesterol, and cellular waste products accumulate in the 
damaged area, inducing endothelial cells to produce pro-inflammatory cytokines. 
As a response to this inflammation, leukocytes adhere to the endothelial layer 
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[51]. This may cause the production of cytokines including IL-2. Based on our 
finding that IL-2 increases SMC proliferation in vitro, exposure of VSMC’s to IL-2 
during an inflammatory event would cause them to proliferate, causing 
fibromuscular lesions, which are characterized as abnormal growth within the 
vessel wall. As a result of this process, the artery wall thickens, leading to 
reduced blood flow, which may contribute to atherosclerosis or restenosis. Our 
lab has previously described the binding of IL-2 to heparan sulfate (HS) 
carbohydrates within the blood vessel wall [3]. Cleavage of the HS carbohydrates 
by heparanase was shown to release biologically active IL-2.  Liberation of HS-
bound IL-2 by heparanase released by T-cells during extravasation through the 
vessel wall could, in turn, induce the proliferation of VSMCs [3]. 
Previous work has demonstrated that SMC’s produce multiple 
immunoregulatory factors including IL-6, IL-8, and TNF- α [52, 53, 54, 55].  Given 
these previous studies, future work assessing the ability of VSMC’s to produce 
IL-2, which could work in an autocrine fashion as it does with T cells is 
reasonable. The current work demonstrates the involvement of the Beta subunit 
of the IL-2R in binding IL-2.  Expanding these studies to assess involvement of 
the alpha and possibly the gamma subunits would better define the interaction of 
IL-2 with the IL-2R expressed on VSMC’s. One approach would be to assess 
how small interfering RNA (siRNA) specific for the alpha, beta, or gamma 
subunits affect the ability of SMC’s to proliferate in response to exposure to IL-2 
in vitro. In addition, determining if IL-2 induces the proliferation of vessel 
endothelial cells would provide a broader vision of the influence of IL-2 on non-
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lymphoid cells of the vasculature. The aortas of IL-2 deficient mice are 
characterized by an abnormal cytoarchitecture of the SMC layer [3] suggesting 
that IL-2 may have an effect on the development or maintenance of a normal 
vessel wall. In addition, smooth muscle cell α-actin (SMC α-actin) is a protein 
known to play a critical role in the differentiation of VSMC. Determining if 
administration of IL-2 to IL-2 knock-out mice results in a more normal VSMC 
layer and the expression of SMC α-actin would allow an assessment of the role 
played by IL-2 during blood vessel development. Understanding the mechanisms 
that regulate expression of the IL-2R by VSMCs and how binding of this receptor 
by IL-2 effects VSMC biology will provide a better understanding of the 
mechanisms underlying vascular development and diseases of the vasculature 
such as atherosclerosis, and restenosis.  
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Figures 
 
 
 
 
 
 
Figure 1. Human Vascular Smooth Muscle Cells Express the Alpha (α), Beta 
(β) but not the Gamma (γ) subunit of IL-2R. Using in-cell Western analysis, 
cultured VSMCs were probed with antibodies directed against α, β, and γ 
subunits of the IL-2R. Isotype indicates biotinylated mouse IgG, and control 
indicates cells alone with no antibodies. Error bars represent the means ± SD of 
triplicate wells, and representative of 3 separate experiments. Analysis of variance 
(ANOVA): P < 0.05 
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Figure 2. VSMCs bind dye-labeled glycosylated IL-2 via IL-2R β.   
Cultured VSMCs were probed with dye labeled glycosylated IL-2 after pre-
incubation with or without anti- IL-2R β antibodies. Error bars represent the 
means ± SD of triplicate wells, and representative of 3 separate experiments.  
Analysis of t test: **(P < 0.05).   
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Figure 3. VSMCs bind dye-labeled non-glycosylated IL-2 via IL-2R β. 
Cultured VSMCs were probed with dye labeled non-glycosylated IL-2 after pre-
incubation with or without anti- IL-2R β antibodies. Error bars represent the 
means ± SD of triplicate wells, and representative of 3 separate experiments. 
Analysis of t test: *(P < 0.05).  
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Figure 4. Exposure of VSMCs to lipopolysaccharide decreases IL-2Rβ 
expression. Using in-cell Western analysis, cultured vascular smooth muscle 
cells were probed with an antibody directed against the β subunit of the IL-2R 
after 48 hours incubation with lipopolysaccharide (LPS; 1 ug/ml). Isotype 
indicates biotinylated mouse IgG, and control indicates cells alone with no 
antibodies. Error bars represent the means ± SD of triplicate wells, and 
representative of 3 separate experiments. Analysis of t test: **(P < 0.05) 
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Figure 5. Treatment of Vascular Smooth Muscle Cells with IL-2 increases 
expression of the IL-2R gamma subunit . Using in-cell Western analysis, 
cultures were probed with an antibody directed against the gamma subunit of the 
IL-2R following 24 hours incubation with IL-2 (4 ng/ml). Isotype indicates 
biotinylated mouse IgG, and control indicates cells alone with no antibodies. 
Error bars represent the means ± SD of triplicate wells, and representative of 3 
separate experiments. Analysis of t test:  **(P < 0.05) 
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Figure 6: Exposure of Vascular Smooth Muscle Cells to IL-2 increases SMC 
Proliferation.  
 VSMCs incubated for 48 hours with 25ng/ml IL-2 or media alone. Proliferation of 
VSMCs was assessed by MTS-based assay” CellTiter 96 One Aqueous Solution 
Cell Proliferation Assay”. Error bars represent the means ± SD of triplicate wells, 
and representative of 4 separate experiments. Analysis of t test:  ****(P < 0.05)  
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Appendix A 
 
In-Cell Western Protocol 
 
Materials required: 
 
Fixative: Ice-cold Methanol with 2% v/v Acetic Acid. 
 
Assay Buffer: Tris-baffered Saline + 0.1% Tween (TTBS) 
 
1) Gently wash plate 1X with PBS (100 L/well) 
 
2) Fix for 5 minutes in ice-cold Methanol with 2% v/v Acetic Acid (100 L/well).  
After fixation, put the plate in the fridge for 5 mins. 
 
3) Gently wash 3X with PBS (100 L/well). 
 
4) Block for 2 hours at room temperature with Odyssey block solution with 1% v/v 
Mouse serum (150 L/well). 
 
5) Wash 3X with TTBS (100uL/well). 
 
6) Incubate wells with primary antibodies suspended in TTBS overnight at room 
temperature. 
 
Antibody   Concentration/ml 
Anti-alpha    10g/ml 
Anti-Beta    10g/ml 
Anti-Gamma    10g/ml 
 
 
 37 
Next Day 
 
7) Wash wells 3X with TTBS (100 L/well).  
 
8) To detect biotinylated antibodies, probe wells with Avidinylated secondary 
used at 10g/ml. Incubate for 1.5 hours at room temperature.   
 
9) Wash the plate 3X with TTBS. 
 
10) Read the plate immediately. 
 
11) Place in dry dark place (closed drawer) and allow to dry overnight for 16 
hours. 
 
11) Re-read dry plate the next morning. 
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Appendix B 
 
IL-2 Binding Studies  
 
 
Materials Required: 
 
Fixative: Ice-cold Methanol with 2% v/v Acetic Acid. 
 
Assay Buffer: PBS only 
 
Protocol: 
1) Wash wells 2X with PBS. 
 
3) Pre-incubate 500ng/ml fluor IL-2 for 20 minutes at 4C.  
 
4) Wash wells 3X with PBS. 
 
5) Place 100 L of Fix solution in each well and incubate at 4C for 15 minutes. 
 
6) Wash wells 2X with PBS. 
 
7) Read on Synergy (wet). 
 
8) Allow wells to air dry in the dark and re-read (dry). 
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Appendix C 
 
SMC Proliferation Studies 
 
1- Maintain a plate of SMCs in SMC medium supplemented with 25ng/ml human 
recombinant IL-2 for 48 hours.  
 
2- Thaw the CellTiter 96® AQueous One Solution Reagent. It should take 
approximately 90 minutes at room temperature, or 10 minutes in a water bath at 
37°C, for completely thawing.  
3- Pipet 20μl of CellTiter 96® AQueous One Solution Reagent into each well of 
the 96-well assay plate containing the SMC cells in 100μl of SMC medium.     
4- Incubate the plate at 37°C for 1–4 hours in a humidified, 5% CO2 atmosphere.  
5- Record the absorbance at 490nm using a 96-well Synergy plate reader. 
 
 
 
 
 
 
 
 
 
 
 
 
 
